Monday, May 13, 2024 7:07:42 PM
Whalatane
Member Level
Re: None
Monday, May 13, 2024 6:59:02 PM
Post# of 251809
UNCY pivotal trial update
By my calculations this pivotal trial will end this weekend.
What remains is data checking / cleaning and then publishing results
Some background . High serum phosphorous is a continuing problem for most ( 85 % ) on dialysis due to kidney failure .
This is because almost all the patients currently taking the Pho binders hate them either because of taste ( chewed with meals ) or pill burden ( up to 12 pills a day )
Recently ARDX managed to get Xphazoh approved ...2 small pills swallowed not chewed ( one at breakfast , 1 at dinner ) While many Nephrologist want to try this drug there are 2 problems .
1) Diarrhea in half the patients for the first 2-3 wks
2) Cost if you are on Medicare / Medicaid . Medicare / Medicaid means patients can't use the coupons ARDX is currently handing out and their copay pay ( This is a tier 5 drug ) is roughly $1,000 a month .
None of the patients my wife's sees are willing to pay the copay as most are Medicare / Medicaid.
Now comes UNCY's OLC .
OLC is a new form of Fosrenol that they wife already prescribes if patients refuse Selevmar ( lowest priced generic )
The advantage of OLC is that its 1 small pill with each meal ...SWALLOWED ( this makes a difference re adherence ) ...not chewed or in powder form mixed with applesauce.
OLC is very effective at lowering serum Pho .
The problem is stomach upsets / nausea .
UNCY's final trial ..results due soon see above ..is all about tolerability .
Can they slowly increase the dose to gradually get serum Pho down to target and keep patients on the drug ?
My guess is that PPS will either drop to 50c or head towards $5 ...depending on results
Risk only what you can afford to lose and forget me if this fails ..:--)
Kiwi
Recent UNCY News
- Unicycive Therapeutics Delivers Multiple Presentations on Oxylanthanum Carbonate (OLC) and UNI-494 at the European Renal Association Congress • GlobeNewswire Inc. • 05/28/2024 11:03:00 AM
- Unicycive Therapeutics to Participate in a Fireside Chat at the Lytham Partners Spring 2024 Investor Conference • GlobeNewswire Inc. • 05/23/2024 11:03:00 AM
- Unicycive Therapeutics Presents Bioequivalence Data on Oxylanthanum Carbonate (OLC) at the National Kidney Foundation Spring Clinical Meeting • GlobeNewswire Inc. • 05/15/2024 11:03:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 05/13/2024 08:28:00 PM
- Unicycive Announces First Quarter 2024 Financial Results and Provides Business Update • GlobeNewswire Inc. • 05/13/2024 08:16:34 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 05/13/2024 08:06:00 PM
- Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) material • Edgar (US Regulatory) • 05/08/2024 08:05:39 PM
- Unicycive Therapeutics to Present at the Noble Capital Markets Emerging Growth Virtual Healthcare Equity Conference • GlobeNewswire Inc. • 04/10/2024 11:03:00 AM
- Unicycive Therapeutics Announces Full Year 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 03/28/2024 08:15:00 PM
- Unicycive Therapeutics to be Featured in Multiple Presentations at the Upcoming European Renal Association Congress • GlobeNewswire Inc. • 03/25/2024 11:03:00 AM
- Unicycive Announces $50 Million Private Placement • GlobeNewswire Inc. • 03/14/2024 11:03:00 AM
- Unicycive Therapeutics Delivers Both an Oral and Poster Presentation on UNI-494 at the AKI and CRRT Conference • GlobeNewswire Inc. • 03/13/2024 11:03:00 AM
- Unicycive Therapeutics Completes Enrollment in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) • GlobeNewswire Inc. • 03/07/2024 09:12:00 PM
- Unicycive Therapeutics Announces Orphan Drug Designation Granted for UNI-494 by the U.S. Food and Drug Administration for the Prevention of Delayed Graft Function in Kidney Transplant Patients • GlobeNewswire Inc. • 03/04/2024 12:03:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/21/2024 09:06:09 PM
- Unicycive Therapeutics to Present Two Posters on Oxylanthanum Carbonate (OLC) at the Upcoming National Kidney Foundation Spring Clinical Meeting • GlobeNewswire Inc. • 02/14/2024 12:03:00 PM
- Unicycive Therapeutics Announces Both an Oral and Poster Presentation to be Delivered on UNI-494 at the Upcoming AKI and CRRT Conference • GlobeNewswire Inc. • 01/29/2024 12:03:00 PM
- Unicycive Therapeutics Issues Shareholder Letter to Highlight Corporate Progress and Key Upcoming Milestones • GlobeNewswire Inc. • 01/23/2024 12:03:00 PM
- Form SC 13G - Statement of acquisition of beneficial ownership by individuals • Edgar (US Regulatory) • 01/22/2024 09:27:47 PM
- Unicycive Therapeutics Announces Enrollment of First Patient in Pivotal Clinical Trial for Oxylanthanum Carbonate (OLC) in Patients with Chronic Kidney Disease on Dialysis • GlobeNewswire Inc. • 12/18/2023 12:03:00 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 12/08/2023 09:36:22 PM
- Unicycive Therapeutics to Participate in Two Investor Conferences in December 2023 • GlobeNewswire Inc. • 11/29/2023 12:03:00 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/14/2023 09:20:39 PM
- Unicycive Announces Third Quarter 2023 Financial Results and Provides Business Update • GlobeNewswire Inc. • 11/14/2023 09:15:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 10/23/2023 03:12:50 PM
Branded Legacy Secures Exclusive Extraction Partnership with One of the World's Largest Kava Distributors and Producers • BLEG • May 30, 2024 8:30 AM
ECGI Holdings, Inc. Announces $2 Million Debt-to-Equity Conversion • ECGI • May 30, 2024 8:30 AM
North Bay Resources Reports Assays up to >25% Mg, 0.1% Ni, 0.1% Cu, 0.01% Co, 0.3 ppm Pt at Tulameen Platinum Project, British Columbia • NBRI • May 29, 2024 9:03 AM
One World Products, Inc. Issues Shareholder Update • OWPC • May 29, 2024 8:20 AM
Green Leaf Innovations, Inc. Engages Olayinka Oyebola & Co for Two-Year Audit • GRLF • May 28, 2024 8:30 AM
HealthLynked Introduces AI-Powered Chat Function to Enhance Healthcare Accessibility • HLYK • May 28, 2024 8:00 AM